Axenis Immunodeficient Mouse Strain Portfolio

25 Sep 2018: genOway acquired Axenis... | Go to Press Release

Genetically Modified Immunodeficient Mouse Models





Our Axenis immunodeficient mouse model portfolio is based on the proprietary state-of-the-art BRGS™ mouse model and consists of the following strains:

  • BRGS (BALB/c Rag2tm1Fwa Il2rgtm1Cgn SirpaNOD)
  • BRGSF (BALB/c Rag2tm1Fwa Il2rgtm1Cgn SirpaNOD Flt3tm1lrl)
  • BRGSF HLA-A2tg (genetically humanized for HLA-A2HHD–Tg(HLA-A/H2-D/B2M)1Bpe)
  • BRGSF HLA-DR2tg (genetically humanized for HLA-DR2–Tg(HLA-DR2)Lfug)
  • BRGSF HLA-A2tg HLA-DR2tg (double-humanized for HLA-A2HHD/DR2)


Reconstituted, Humanized Axenis Mice–Specific Tools for Human Biomedical Research


Get supplemental information, a quote, and estimated timeframe for generating your Axenis HIS mouse.



Axenis immunodeficient humanized mouse models offer new opportunities to address human-specific questions in a more relevant manner, facilitating translational research in several biomedical disciplines and approaches.

Axenis BRGS/BRGSF mice are excellent recipients for human hematopoietic cells. We routinely generate BRGS/BRGSF mice humanized for the immune system (HIS), using human CD34+ hematopoietic progenitor cells.

The Axenis BRGS/BRGSF-HIS mice contain all major human hematopoietic cell subsets, such as B cells, T cells (including CD4+ Treg cells), NK cells, and the myeloid compartment including dendritic cells (DCs), plasmacytoid cells (pDCs) and monocytes/macrophages.

Optimized formats of the Axenis BRGS/BRGSF-HIS mice are:

  • BRGSF-DC – boosted for human dendritic cell content
  • BRGS/BRGSF-ImStim – for robust immune responses
  • BRGS/BRGSF-NK – boosted for human NK cell content

The human myeloid compartment can be boosted with a simple exogenous Flt3-ligand treatment in BRGSF mice that lack the corresponding mouse receptor (Flk2/Flt3). The boost of human dendritic cell accumulation potentiates human T cell function.


Strategy for HIS mouse generation

Human cell-boosting options in Axenis BRGS/BRGSF-HIS mice

Applications of Axenis BRGS/BRGSF-HIS mice

BRGS/BRGSF mouse models are in use for studies in fields such as:

  • Immunology
  • Inflammation
  • Vaccine & drug screening
  • Physiopathology of infectious diseases
  • Personalized medicine
  • Stem cell transplantation
  • Gene therapy
  • Oncology
  • Drug development

Studies can span from the earliest R&D to preclinical safety/efficacy development stages. Performing screening on components of the human immune system in an in vivo context is likely to yield results that will more reliably predict human responses, as compared to those obtained using “standard” rodent models.

We design custom-made models that meet the specific needs of our customers. Exploratory work, as well as late preclinical studies, are performed in areas of activity such as:

  • Hematopoietic efficacy/safety profiling of drugs and biologicals: covers molecules such as vaccines, adjuvants, biosimilars, small synthetic molecules, monoclonal antibodies, new formulations – in a variety of application fields
  • Infectious diseases: humanized mice can support infection by a variety of human-tropic pathogens (e.g. HIV, CMV, RSV, EBV, Dengue virus, HTLV, etc.) and host–pathogen interactions, as well as new therapeutics, can be evaluated directly in BRGS-HIS mice
  • Oncology: BRGS mice are particularly permissive to human tumor xenograft transplantation, and host–tumor interactions, as well as evaluation of therapeutics that require the presence of both a tumor and human immune cells can be evaluated in BRGS-HIS mice


Valton J, Guyot V, Boldajipour B, Sommer C, Pertel T, Juillerat A, Duclert A, Sasu BJ, Duchateau P, Poirot L.
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies.
Sci Rep. 2018 Jun 12.

Fournier N, Jacque E, Fontayne A, Derache D, Dupont G, Verhaeghe L, Baptista L, Dehenne A, Dezetter AS, Terrier A, Longue A, Pochet-Beghin V, Beghin C, Chtourou S, de Romeuf C.
Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.
MAbs. 2018 May/Jun.

Fior J.
SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice.
Vaccines (Basel). 2016 Apr 26.

Li Y, Mention JJ, Court N, Masse-Ranson G, Toubert A, Spits H, Legrand N, Corcuff E, Strick-Marchand H, Di Santo JP.
A novel Flt3-deficient HIS mouse model with selective enhancement of human DC development.
Eur J Immunol. 2016 May.

Strick-Marchand H, Dusséaux M, Darche S, Huntington ND, Legrand N, Masse-Ranson G, Corcuff E, Ahodantin J, Weijer K, Spits H, Kremsdorf D, Di Santo JP.
A novel mouse model for stable engraftment of a human immune system and human hepatocytes.
PLoS One. 2015 Mar 17.

Legrand N1, Huntington ND, Nagasawa M, Bakker AQ, Schotte R, Strick-Marchand H, de Geus SJ, Pouw SM, Böhne M, Voordouw A, Weijer K, Di Santo JP, Spits H.
Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo.
Proc Natl Acad Sci U S A. 2011 Aug 9.